Probiotics work, but not as a category. The evidence is strain-specific and condition-specific: a few strains have solid trial support for antibiotic-associated diarrhoea, some help irritable bowel syndrome modestly, and most of the bottles on the shelf have never been tested for the claim on the label. Here is what five common benefits are actually worth, strain by strain.
Medically reviewed by Dr. A. Collins, MDBoard Certified Internist · Updated 26 October 2026
What probiotics actually are

Probiotics are live microorganisms that, when given in adequate amounts, confer a health benefit. Every part of that definition matters. Live means a dead product does nothing. Adequate amounts means the dose in the trial, not a token count on a label that has often faded by the time you open it. Health benefit means it has to be demonstrated, not assumed from the species name.
The practical consequence is that “probiotics” is not one intervention any more than “antibiotics” is. Lactobacillus rhamnosus GG is not interchangeable with a generic blend of six species, even if both bottles say “probiotic” in the same font size.
Why the strain is the whole argument
A systematic review examining strain-specificity and disease-specificity of probiotic efficacy reached a conclusion that undermines most marketing: the effects of probiotics are largely specific to particular strains for particular conditions, and results cannot be generalised across strains or across diseases (McFarland, 2018).
L. rhamnosus GG
Decades of trials, strongest for preventing antibiotic-associated diarrhoea. Sold under many brands with wildly different doses.
Good evidence
S. boulardii
A yeast, not a bacterium. Reasonable evidence in antibiotic-associated diarrhoea, and often recommended alongside antibiotics.
Good evidence
Multi-strain blends
Results depend entirely on which strains and which doses. A “10 billion CFU, 8 strains” label tells you almost nothing about efficacy.
Depends entirely
Generic lactobacillus
Species-level claims without strain identification are a marketing category, not an evidence category.
Unproven
The five benefits, graded
The article’s headline promises five benefits. Grading them honestly is more useful than listing them enthusiastically.
1. Antibiotic-associated diarrhoea
Supported. Systematic reviews find probiotics reduce the risk of antibiotic-associated diarrhoea when co-prescribed with antibiotics (Goodman, 2021), with adult meta-analyses reaching the same direction (Liao, 2021). This is the strongest indication and the one with the clearest clinical rationale.
Grade A
2. Irritable bowel syndrome
Modest, real, inconsistent. A systematic review and meta-analysis found probiotics produce small improvements in IBS symptom scores, with substantial variation between strains and trials (Goodoory, 2023). Worth a trial; not a reliable fix.
Grade B
3. Immune support and upper respiratory infections
Weakly supported. A Cochrane review found probiotic use was associated with fewer upper respiratory infections and fewer antibiotic prescriptions, with low to moderate certainty evidence (Zhao, 2022). The effect is modest and the marketing overstates it.
Grade B–
4. Gut-brain effects and mood
Early and overstated. The gut-brain axis is real biology; whether a commercial probiotic capsule improves mood is not established, and popular claims outrun the trials by a wide margin. The underlying relationship is covered in the gut-brain connection.
Grade C
5. Weight loss and metabolic benefits
Not supported as a weight-loss intervention. Reviews of probiotics alongside prebiotics, synbiotics and faecal transplant show some metabolic signal, but nothing resembling a weight-loss effect worth buying a supplement for (Wu, 2024).
Grade C
Where probiotics disappoint
Three patterns explain most failed probiotic attempts, and none of them are the consumer’s fault.
- The strain was never tested for that condition. The supermarket shelf is full of species-level claims that rest on trials of a different strain.
- The dose is too low, or already dead. Trials use defined doses at the time of manufacture; a product on a warm shelf may contain far fewer viable organisms than the label promises.
- Colonisation is usually temporary. Most probiotic strains pass through rather than taking up residence, which is why benefit typically requires ongoing use rather than a single course.
Safety: who should not take them
Probiotics are well tolerated by most healthy adults, and serious events are rare. Two cautions matter more than the average risk profile suggests.
- People who are severely immunocompromised — transplant recipients, those on intensive chemotherapy, premature infants, critically ill patients on central lines. Live organisms can, rarely, translocate and cause bloodstream infection in this group. This is a well-recognised clinical precaution rather than a consumer-level concern.
- People with a central venous catheter — a documented risk factor for probiotic-associated infection, and the main reason hospitals restrict them.
- Anyone with significant illness who is considering a new supplement — ask the treating team, because the risk calculus in hospital is not the same as at home.
Choosing a product that is actually tested
- Look for the full strain designation. Genus, species and strain code — for example Lactobacillus rhamnosus GG. A label with only the genus and species is telling you the evidence does not apply.
- Match the strain to the condition. A product marketed for “general gut health” is not the same as one tested for antibiotic-associated diarrhoea.
- Check CFU at the end of shelf life, not at manufacture. These are different numbers and only one of them describes what you are buying.
- Prefer products with a stated trial reference. Reputable manufacturers cite the specific study their strain was used in.
- Ignore “colon cleanse” framing. That is a different marketing category with no trial basis.
Food first, and it does help
Fermented foods contain live cultures, but they are not standardised — the species and counts vary by product, batch and storage. That makes them poor substitutes for a specific tested strain when you need one, and a perfectly reasonable addition to a normal diet otherwise.
The distinction between probiotics, prebiotics and postbiotics is genuinely confusing and worth getting straight, since the three are often sold in the same aisle. That is covered in prebiotics versus probiotics versus postbiotics, and the practical food side in the fermented foods guide.
Where fibre matters more than any capsule is set out in how carbohydrates power the body.

Where this fits in gut health

Probiotics are one lever among several, and usually not the biggest one. Fibre intake, fermented foods, sleep and not overusing antibiotics all matter more for most people than which capsule they choose.
Conditions that are genuinely driven by bacterial overgrowth — small intestinal bacterial overgrowth among them — often need a different approach entirely, set out in SIBO explained. The barrier question is covered in leaky gut symptoms, and the skin connection in the gut-skin axis.
For the supplement category broadly, including how to judge a label, see the immune supplement guide, the sea moss review, the vitamins guide and the First Day vitamins review.
Specific situations worth knowing
Beyond the headline benefits, a few narrower uses have enough evidence to be worth knowing about — and each comes with a limit that the marketing usually omits.
Travellers’ diarrhoea
Some protection has been shown for specific strains, but the effect depends heavily on destination and the organism involved, and it is not a substitute for food and water hygiene. If you are travelling to a high-risk area, this is a conversation to have before you go rather than a bottle to buy at the airport.
Preventing C. difficile recurrence
Recurrent Clostridioides difficile infection has become the strongest argument for microbiome-directed treatment, but the effective intervention is faecal microbiota transplantation under medical supervision rather than an over-the-counter capsule. Probiotic co-prescription is used in some settings; self-treatment is not appropriate for a condition that can be life-threatening.
Infants and children
The paediatric evidence base is real. A Cochrane review found probiotics reduce the risk of antibiotic-associated diarrhoea in children, with L. rhamnosus GG and S. boulardii among the better-studied strains (Guo, 2019). Doses are weight-adjusted and products differ, so this is a paediatrician conversation rather than a supermarket decision.
Vaginal health
Specific lactobacillus strains have trial support for preventing recurrent bacterial vaginosis and vulvovaginal candidiasis, particularly when used alongside standard treatment. Strain identity matters more here than anywhere, because the species that colonise the vagina are not the ones that colonise the gut.
Why LGG keeps appearing
One strain dominates the literature because it was characterised early and studied for three decades — a review of thirty years of Lactobacillus rhamnosus GG sets out both the breadth of that work and its limits (Capurso, 2019). That history is why LGG appears in so many products, and it is also why other strains have thinner evidence: not because they are worse, but because they have been studied less.
What to expect, and when to stop
Most of the benefit, where there is any, appears within the first two to four weeks. That gives you a reasonable trial period and a reasonable stopping rule.
- Week one. Mild bloating and increased wind are common as the gut population shifts. This usually settles; it is not a reason to stop on day three.
- Weeks two to four. This is the window in which a real effect on diarrhoea or IBS symptoms should be visible. If nothing has changed, the strain is probably not working for you.
- Beyond four weeks without benefit. Stop. Continuing to buy a product that has not helped is the most common waste in this category.
- Stop immediately if you develop fever, abdominal pain or any sign of infection while immunocompromised, and speak to a doctor.
One practical point about cycling: because most strains do not colonise permanently, benefit generally requires continued use. That means the cost is ongoing, which changes the calculation — a supplement that helps slightly is worth less if it has to be bought forever.
Common questions about probiotics
Do probiotics actually work?
Some do, for some conditions. Antibiotic-associated diarrhoea has the strongest evidence. IBS shows small benefits. Weight loss, mood and general “immunity” claims are much weaker than the packaging suggests.
When should I take them with antibiotics?
Usually spaced a couple of hours apart from the antibiotic dose, and continued for a few days after the course. The specific strain and duration used in trials vary, so follow the product’s trial reference where it provides one.
Are probiotics safe?
For most healthy adults, yes, with mild bloating in the first week being the most common issue. They are a genuine concern in severely immunocompromised people and those with central lines.
Do I need to refrigerate them?
Follow the label. Some strains are shelf-stable, others lose viability quickly. A product that requires refrigeration but was shipped warm may not contain what it claims.
Are expensive probiotics better?
Not automatically. Price tracks marketing more than evidence. What matters is the specific strain, a dose matching the trials, and viability to end of shelf life.
Can I get the same benefit from yoghurt?
Yoghurt supplies live cultures but rarely the specific tested strain at a trial-level dose. It is a good food, not a substitute for a targeted probiotic when one is indicated.
Sources
- McFarland LV, et al. Strain-specificity and disease-specificity of probiotic efficacy: a systematic review and meta-analysis. Front Med. 2018. PMID 29868585
- Goodman C, et al. Probiotics for the prevention of antibiotic-associated diarrhoea: a systematic review and meta-analysis. BMJ Open. 2021. PMID 34385227
- Liao W, et al. Probiotics for the prevention of antibiotic-associated diarrhea in adults: a meta-analysis. J Clin Gastroenterol. 2021. PMID 33234881
- Goodoory VC, et al. Efficacy of probiotics in irritable bowel syndrome: systematic review and meta-analysis. Gastroenterology. 2023. PMID 37541528
- Zhao Y, et al. Probiotics for preventing acute upper respiratory tract infections. Cochrane Database Syst Rev. 2022. PMID 36001877
- Wu Y, et al. The efficacy of probiotics, prebiotics, synbiotics and fecal microbiota transplantation. Nutrients. 2024. PMID 38999862
- Guo Q, et al. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev. 2019. PMID 31039287
- Capurso L. Thirty years of Lactobacillus rhamnosus GG: a review. J Clin Gastroenterol. 2019. PMID 30741841




